Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
CLSD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $1.65
Previous CloseN/A
Volume106.43K
Average Volume (3M)157.69K
Market Cap
$67.21M
Enterprise Value$104.51M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding77,279,290
10 Day Avg. Volume97,440
30 Day Avg. Volume157,694
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.70
Forecast
1Y Price Target
$5.80Price Target Upside551.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Clearside Biomedical News
PremiumCompany Announcements
Clearside Biomedical Reports 2024 Earnings and Strategic Progress
PremiumCompany Announcements
Clearside Biomedical Reports 2024 Financial Results and Updates
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase 2b ODYSSEY trial of CLS-AX in wet AMD reported positive topline results.
FDA AlignmentFDA has approved the proposed phase 3 program for CLS-AX in wAMD, supporting the company's trial design.
Industry EngagementClearside Biomedical Inc has participated in key industry conferences, showcasing its commitment to engaging with the healthcare community.
Bears Say
Financial StabilityThe cash available at the end of 2024 provides a financial runway only into the fourth quarter of the following year.
Funding RequirementsThe company needs to raise capital to fund the Phase 3 program.
Phase 3 ChallengesThe initiation of the phase 3 program is contingent on securing additional financing or entering into a development collaboration.
---
Ownership Overview
1.80% Insiders
4.84% Mutual Funds
0.18% Other Institutional Investors
89.41% Public Companies and
Individual Investors
CLSD FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.70 and its highest was $1.65 in the past 12 months.
What is Clearside Biomedical’s market cap?
Clearside Biomedical’s market cap is $67.21M.
When is Clearside Biomedical’s upcoming earnings report date?
Clearside Biomedical’s upcoming earnings report date is May 08, 2025 which is tomorrow.
How were Clearside Biomedical’s earnings last quarter?
Clearside Biomedical released its earnings results on Mar 27, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.098 by -$0.002.
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 77,279,290 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Clearside Biomedical reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.098. Following the earnings report the stock price went down -7.767%.
Which hedge fund is a major shareholder of Clearside Biomedical?
Currently, no hedge funds are holding shares in CLSD
---
Clearside Biomedical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (551.69% Upside)
$5.80 (551.69% Upside)
Insider Transactions
Bought Shares
Worth $13.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.29%
12-Months-Change
Fundamentals
Return on Equity
91.63%
Trailing 12-Months
Asset Growth
-26.14%
Trailing 12-Months
Company Description
Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
---
CLSD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and regulatory approvals, particularly in the Asia-Pacific region. However, the company faces challenges in securing funding for its Phase 3 program, which is crucial for its future success. The sentiment is positive due to the strong trial results and strategic partnerships, despite the funding and enrollment challenges.Read More>---
CLSD Stock 12 Month Forecast
Average Price Target
$5.80
▲(551.69% Upside)
Technical Analysis
---